Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

20181,375 citationsJournal Articlebronze Open Access

Authors

Willemien J. van Driel · Gynecologic Oncology Group

Simone N. Koole · The Netherlands Cancer Institute

Karolina Sikorska · Norwegian Womens Public Health Association

Jules H. Schagen van Leeuwen · Gynecologic Oncology Group

Henk W.R. Schreuder · Gynecologic Oncology Group

Ralph H.M. Hermans · Gynecologic Oncology Group

Ignace H. J. T. de Hingh

Abstract

Among patients with stage III epithelial ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone and did not result in higher rates of side effects. (Funded by the Dutch Cancer Society; ClinicalTrials.gov number, NCT00426257 ; EudraCT number, 2006-003466-34 .).

Topics & Keywords

Intraperitoneal and Appendiceal Malignancies Ovarian cancer diagnosis and treatment Testicular diseases and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 3, pp. 230-240

DOI: 10.1056/nejmoa1708618

Field-Weighted Citation Impact: 157.42